Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LILAC: AbeLacimab in High-Risk Atrial Fibrillation Unsuitable for Oral Anticoagulation
jRCT2031230045Phase 3Recruiting
- Sponsor
- Anthos Therapeutics
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) and atrial flutter (AFL) comparing Abelacimab arm with Placebo arm (2 arms). Started Sep 2023; status: recruiting.
02
Drugs
abelacimab
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on jRCT2031230045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230045.